Women Enrollment In Phase I/II Trials Continues To Be Low, GAO Says
Executive Summary
Women continue to be under-represented in early phase safety studies, a General Accounting Office report on women in clinical trials suggests.
You may also be interested in...
FDA’s Dubious Honor: GAO Flags Many Of Its Activities As “High Risk”
FDA's White Oak campus is still far from complete, but an extreme reading of official statements during the last few weeks might suggest that it could be closed
FDA’s Dubious Honor: GAO Flags Many Of Its Activities As “High Risk”
FDA's White Oak campus is still far from complete, but an extreme reading of official statements during the last few weeks might suggest that it could be closed
PK/PD Studies Should Routinely Include Women, FDA Says
Women should be routinely included in pharmacokinetic and pharmacodynamic studies performed in Phase I and II trials, FDA said April 18.